GlassScriptPhysician profile
Gaurav Parikh
NPI 1144494550
$1,988.07
in general payments reported to CMS, 2019-2025
27 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $205 · 2021: $162 · 2022: $564 · 2023: $313 · 2024: $299 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $274.42 | 2019-2025 | |
| Medtronic, INC. | $244.38 | 2022-2023 | Corevalve Evolut R |
| Shockwave Medical, INC | $200.48 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $165.20 | 2019-2020 | |
| Stryker Corporation | $132.86 | 2025 | Flowtriever, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Teleflex LLC | $119.04 | 2020-2023 | Guideliner |
| Amarin Pharma, INC. | $95.62 | 2020-2021 | |
| Boston Scientific Corporation | $84.76 | 2022-2025 | General - Balloon Catheters, Watchman Flx |
| Pfizer INC. | $78.00 | 2024 | |
| Chiesi USA, INC. | $76.61 | 2020-2025 | Kengreal, Cleviprex |
| Abiomed | $75.22 | 2020-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $53.17 | 2019-2024 | Farxiga |
| Cardiva Medical, INC. | $44.67 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Inari Medical, INC. | $41.46 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kiniksa Pharmaceuticals, LTD. | $40.90 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.87 | 2022-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $28.77 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $27.12 | 2022 | |
| Novo Nordisk INC | $25.00 | 2023 | Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $23.10 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $19.30 | 2024 | Verquvo |
| Scpharmaceuticals INC. | $18.79 | 2025 | |
| Kestra Medical Technology Services, INC. | $18.35 | 2025 | Assure Wcd |
| Abbott Laboratories | $17.30 | 2022 | |
| Livanova USA, INC. | $16.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.72 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.